Alcon drops AMD candidate

Article

Following disappointing clinical trial results, Alcon has discontinued its plans to develop anecortave acetate for the prevention of choroidal neovascularization secondary to age-related macular degeneration (AMD).

Following disappointing clinical trial results, Alcon has discontinued its plans to develop anecortave acetate for the prevention of choroidal neovascularization secondary to age-related macular degeneration (AMD).

At the 24-month time point, the compound, which was tested in 2546 patients, had failed to achieve both primary and secondary endpoints, causing Alcon to discontinue four separate studies that were being conducted in the US and Asia.

Although Alcon will no longer study the efficacy of anecortave acetate in the treatment of AMD, the company plans to continue its study of the compound as an anterior juxtascleral depot for the reduction of intraocular pressure in open-angle glaucoma.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.